Clinical Trials Logo

Marginal Zone Lymphoma clinical trials

View clinical trials related to Marginal Zone Lymphoma.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06454968 Recruiting - Clinical trials for Marginal Zone Lymphoma

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Start date: June 20, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab and lenalidomide in untreated marginal zone lymphoma. The primary objective was the best complete response rate (CRR).

NCT ID: NCT06449885 Recruiting - Clinical trials for Marginal Zone Lymphoma

A Cohort Study in Newly Diagnosed MZL

Start date: May 30, 2024
Phase:
Study type: Observational

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

NCT ID: NCT06350318 Recruiting - Follicular Lymphoma Clinical Trials

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Start date: March 13, 2024
Phase: Phase 2
Study type: Interventional

The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).

NCT ID: NCT06340737 Recruiting - Clinical trials for Mantle Cell Lymphoma

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Start date: March 29, 2024
Phase: Phase 1
Study type: Interventional

This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and duration of response (DOR). An evaluable participant is one who completes leukapheresis, lymphodepleting chemotherapy and CART infusion.

NCT ID: NCT06151730 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Start date: January 5, 2024
Phase:
Study type: Observational

This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.

NCT ID: NCT06125028 Recruiting - Clinical trials for Marginal Zone Lymphoma

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

LYMFOR
Start date: June 2024
Phase: Phase 3
Study type: Interventional

This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial to assess the diagnostic performance and safety of the positron emission tomography (PET) imaging agent [68Ga]Ga-PTF) , versus [18F]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma exemplary for CXCR4-positive malignant lymphomas.

NCT ID: NCT06026319 Recruiting - Clinical trials for Mantle Cell Lymphoma

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Start date: October 26, 2023
Phase: Phase 1
Study type: Interventional

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: - CD79b-19 CAR T cells - Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

NCT ID: NCT06014762 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Start date: April 16, 2024
Phase: Phase 1
Study type: Interventional

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

NCT ID: NCT06006117 Recruiting - Clinical trials for Marginal Zone Lymphoma

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Start date: September 5, 2023
Phase: Phase 3
Study type: Interventional

This is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously treated with at least one prior systemic treatment and not more than three prior lines are eligible. Previous treatment line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib. The patients will be Randomized as follows: Arm A - Experimental arm: • Mosunetuzumab-Lenalidomide Arm B - Comparator arms ( Investigator Choices): - Rituximab-Lenalidomide - Rituximab-Bendamustine - Rituximab-CHOP

NCT ID: NCT05846750 Recruiting - Clinical trials for Marginal Zone Lymphoma

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Start date: November 1, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, multicenter clinical study that will enroll 59 patients with relapsed and refractory (R/R) MZL. The study is designed to evaluate the efficacy and safety of the combination of obinutuzumab and lenalidomide in the treatment of relapsed and refractory marginal zone lymphoma (MZL).